PP_1170x120_10-25-21

John Schutte

Acura licenses rights to Nexafed anti-meth decongestant

Acura licenses rights to Nexafed anti-meth decongestant

PALATINE, Ill. — Acura Pharmaceuticals Inc. has entered into a licensing pact that grants exclusive U.S. and Canadian marketing rights to its Nexafed and Nexafed Sinus abuse-resistant decongestant products to MainPointe Pharmaceuticals LLC. Acura said Friday that MainPointe will assume all manufacturing and commercialization activities for the two products. The agreement includes an upfront cash